Analytical Data
-
基因名
ECRG4
- Application
-
别名
C2orf40; Augurin
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9H1Z8
-
表达区间
Asn32~Tyr148
-
分子量
18kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ECRG4, or "Enhanced Cationic Repeat Gene 4," is a gene that has garnered significant interest in the field of cancer research due to its potential role as a tumor suppressor. Initially identified through its downregulation in various malignancies, ECRG4 has been linked to processes such as cell proliferation, apoptosis, and metastasis. Studies suggest that ECRG4 may inhibit cancer progression by modulating signaling pathways associated with cell growth and survival. Its expression levels have been inversely correlated with tumor aggressiveness in several types of cancer, including gastric and colorectal cancers. Given the protein's involvement in the regulation of cellular mechanisms, research has focused on elucidating its functional properties and the molecular pathways it influences. Furthermore, the therapeutic potential of ECRG4 as a biomarker for early diagnosis and a candidate for targeted therapy is currently being explored. Understanding ECRG4's biological functions and its interaction with other cellular components is crucial for developing new strategies in cancer treatment and prevention, making it a promising subject for ongoing and future research endeavors.
